Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GMABNASDAQ:PTGXNYSE:QGENNYSE:RDY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGMABGenmab A/S$20.52+1.1%$21.00$17.24▼$28.56$13.02B0.941.23 million shs1.43 million shsPTGXProtagonist Therapeutics$49.87-2.3%$49.51$32.50▼$60.60$3.16B2.26843,650 shs771,742 shsQGENQIAGEN$47.49-1.8%$44.93$37.63▼$49.30$10.75B0.681.20 million shs1.08 million shsRDYDr. Reddy's Laboratories$15.08$14.75$12.26▼$16.89$12.59B0.331.52 million shs1.84 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGMABGenmab A/S0.00%-0.44%-8.06%+12.20%-20.09%PTGXProtagonist Therapeutics0.00%-8.06%-5.85%+18.49%+51.84%QGENQIAGEN0.00%+1.21%+6.29%+19.87%+20.98%RDYDr. Reddy's Laboratories0.00%+0.13%-2.96%+19.83%-3.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGMABGenmab A/S3.881 of 5 stars3.35.00.00.02.00.03.1PTGXProtagonist Therapeutics2.0923 of 5 stars3.51.00.00.02.52.50.0QGENQIAGEN3.9207 of 5 stars1.25.01.74.52.01.71.3RDYDr. Reddy's Laboratories2.6955 of 5 stars2.54.01.70.01.50.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGMABGenmab A/S 2.67Moderate Buy$37.6083.24% UpsidePTGXProtagonist Therapeutics 3.00Buy$66.1032.54% UpsideQGENQIAGEN 2.30Hold$49.404.02% UpsideRDYDr. Reddy's Laboratories 3.00Buy$16.9512.40% UpsideCurrent Analyst Ratings BreakdownLatest PTGX, GMAB, RDY, and QGEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025QGENQIAGENBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$50.00 ➝ $53.006/24/2025QGENQIAGENBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$55.006/17/2025PTGXProtagonist TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$72.006/5/2025RDYDr. Reddy's LaboratoriesHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/5/2025RDYDr. Reddy's LaboratoriesHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$14.44 ➝ $16.906/3/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.005/19/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.004/21/2025QGENQIAGENRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$42.00 ➝ $43.004/10/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.004/9/2025GMABGenmab A/SHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $37.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGMABGenmab A/S$3.12B4.21$1.53 per share13.39$8.04 per share2.55PTGXProtagonist Therapeutics$434.43M7.11$4.41 per share11.30$11.33 per share4.40QGENQIAGEN$1.98B5.34$3.15 per share15.08$16.05 per share2.96RDYDr. Reddy's Laboratories$325.54B0.04$1.03 per share14.60$4.73 per share3.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGMABGenmab A/S$1.14B$1.7611.6611.536.6935.11%18.08%14.52%8/14/2025 (Estimated)PTGXProtagonist Therapeutics$275.19M$0.7566.49N/AN/A27.04%9.22%8.31%8/5/2025 (Estimated)QGENQIAGEN$83.59M$0.40119.0719.302.464.68%14.61%8.80%7/30/2025 (Estimated)RDYDr. Reddy's Laboratories$663M$0.6622.8518.395.3317.38%17.98%12.24%7/25/2025 (Estimated)Latest PTGX, GMAB, RDY, and QGEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025QGENQIAGEN$0.60N/AN/AN/A$523.97 millionN/A7/25/2025Q1 25/26RDYDr. Reddy's Laboratories$0.19N/AN/AN/A$88.27 billionN/A5/9/2025Q4 24/25RDYDr. Reddy's Laboratories$0.20$0.22+$0.02$0.22$83.70 billion$996.17 million5/8/2025Q1 2025GMABGenmab A/S$0.23$0.31+$0.08$0.31$5.17 billion$715.00 million5/7/2025Q1 2025QGENQIAGEN$0.50$0.55+$0.05$0.41$465.66 million$483.46 million5/6/2025Q1 2025PTGXProtagonist Therapeutics-$0.50-$0.19+$0.31-$0.19$30.44 million$28.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGMABGenmab A/SN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/AQGENQIAGEN$0.250.53%N/A62.50%N/ARDYDr. Reddy's Laboratories$0.070.46%N/A10.61%N/ALatest PTGX, GMAB, RDY, and QGEN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/1/2025QGENQIAGEN$0.250.52%7/2/20257/3/20257/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGMABGenmab A/SN/A5.345.32PTGXProtagonist TherapeuticsN/A17.2517.26QGENQIAGEN0.403.372.83RDYDr. Reddy's Laboratories0.021.921.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGMABGenmab A/S7.07%PTGXProtagonist Therapeutics98.63%QGENQIAGEN70.00%RDYDr. Reddy's Laboratories3.85%Insider OwnershipCompanyInsider OwnershipGMABGenmab A/S1.54%PTGXProtagonist Therapeutics4.90%QGENQIAGEN9.00%RDYDr. Reddy's Laboratories2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGMABGenmab A/S2,682641.22 million631.35 millionOptionablePTGXProtagonist Therapeutics12061.98 million58.95 millionOptionableQGENQIAGEN5,765222.29 million202.29 millionOptionableRDYDr. Reddy's Laboratories27,811834.89 million818.19 millionOptionablePTGX, GMAB, RDY, and QGEN HeadlinesRecent News About These CompaniesRDY - Dr Reddy's Laboratories Ltd ADR Valuation - MorningstarJuly 2, 2025 | morningstar.comMRDY Dr. Reddy's Laboratories Limited - Seeking AlphaJuly 2, 2025 | seekingalpha.comBessemer Group Inc. Purchases 81,024 Shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY)June 27, 2025 | marketbeat.comDr. Reddy's Laboratories slips Thursday, underperforms competitorsJune 26, 2025 | marketwatch.comDr. Reddy's Laboratories Ltd (NYSE:RDY) Shares Sold by Robeco Institutional Asset Management B.V.June 26, 2025 | marketbeat.comDr. Reddy's Laboratories slips Monday, still outperforms marketJune 23, 2025 | marketwatch.comDr. Reddy's Laboratories Ltd (NYSE:RDY) Shares Sold by Ritholtz Wealth ManagementJune 19, 2025 | marketbeat.comGAMMA Investing LLC Purchases 66,049 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)June 17, 2025 | marketbeat.comRhumbline Advisers Sells 86,773 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)June 14, 2025 | marketbeat.comStanley Laman Group Ltd. Makes New $1.85 Million Investment in Dr. Reddy's Laboratories Limited (NYSE:RDY)June 13, 2025 | marketbeat.comDr. Reddy's Laboratories rallies Tuesday, outperforms competitorsJune 10, 2025 | marketwatch.comDr. Reddy's Laboratories Reaches Analyst Target PriceJune 8, 2025 | nasdaq.comHSBC Upgrades Dr. Reddy's Laboratories Limited - Depositary Receipt () (RDY)June 6, 2025 | msn.comHSBC Upgrades Dr. Reddy’s Laboratories Limited (RDY) to Buy from HoldJune 5, 2025 | msn.comDr. Reddy's Laboratories rallies Thursday, outperforms competitorsJune 5, 2025 | marketwatch.comHSBC upgrades Dr Reddy’s on weight loss drug semaglutide-driven earnings reboundJune 5, 2025 | in.investing.comDr. Reddy’s stock rises on biosimilar collaboration with AlvotechJune 5, 2025 | investing.comRDY & ALVO Ink Collaboration Deal for Merck's Keytruda BiosimilarJune 5, 2025 | zacks.comAlvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)June 5, 2025 | businesswire.comAlvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)June 5, 2025 | finance.yahoo.comAlvotech and Dr. Reddy’s partner to co-develop biosimilar candidate for Keytruda (pembrolizumab)June 5, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTGX, GMAB, RDY, and QGEN Company DescriptionsGenmab A/S NASDAQ:GMAB$20.52 +0.22 (+1.08%) As of 04:00 PM EasternGenmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.Protagonist Therapeutics NASDAQ:PTGX$49.87 -1.18 (-2.31%) Closing price 04:00 PM EasternExtended Trading$47.78 -2.10 (-4.20%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.QIAGEN NYSE:QGEN$47.49 -0.85 (-1.76%) As of 03:59 PM EasternQIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.Dr. Reddy's Laboratories NYSE:RDY$15.08 0.00 (0.00%) As of 03:59 PM EasternDr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
